Evidence date · 2026-07-28 · Research note 2 of 3
1 2 3
See current Track status →
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: How a human study will link brain imaging to later diagnoses in REM sleep behavior disorder
Previous expectation: Dependable estimates of progression could support more individualized follow-up for people with REM sleep behavior disorder.
What this study adds: The Milan registry describes a study combining repeated clinical, cognitive, sleep and MRI measurements in people whose disorder was diagnosed at least five years earlier, with matched controls. This adds a specific study design to the timeline without testing the earlier forecast of clinical usefulness.
What changed in this study
A diagnosed sleep disorder can signal an elevated risk of later neurological disease. It is a different question to estimate which person may receive a Parkinson’s disease diagnosis sooner. A ClinicalTrials.gov registry entry describes a Milan study designed to investigate that timing question in people with longstanding idiopathic REM sleep behavior disorder, or iRBD.
The study is not a completed prediction test. It is an observational plan to follow participants over time, combining brain imaging, sleep recordings, clinical assessments and tests of thinking and memory. The goal is to see whether changes across these measurements can help researchers develop a prognostic model for short-term progression to clinically defined Parkinson’s disease.
The study starts with a carefully defined group
The planned patient group includes 50 people whose iRBD was confirmed with polysomnography, a sleep study, and whose diagnosis dates back at least five years. They must not already have clinically defined Parkinson’s disease. The study also plans to include 50 healthy controls matched to the patient group by age and sex. The participants are being assessed at IRCCS Ospedale San Raffaele in Milan, Italy.
That selection determines what the researchers are actually asking. They are studying progression among people who already have a specific, objectively confirmed sleep disorder and have lived with that diagnosis for a substantial period. Time since an iRBD diagnosis is not the same as time since sleep symptoms began, and the study does not represent everyone with poor sleep or nonspecific sleep complaints.
The healthy controls provide a comparison group for the measurements. Their role is to help show how clinical, cognitive, sleep and imaging observations differ between the selected patient group and people without the study’s target disorder. It does not turn the project into a general-population screening study.
Repeated measurements follow the same people
At baseline and once a year for three years, the patients are scheduled for several kinds of assessment. Clinical and motor evaluations record how participants are functioning. Neuropsychological testing examines areas such as memory, attention and other aspects of thinking. Quantitative polysomnography records sleep-related signals over time, allowing the researchers to examine changes in the sleep disorder itself.
The MRI program adds several views of the brain. Structural MRI is intended to track changes in brain anatomy. Diffusion imaging examines white-matter-related features, while resting-state functional MRI is used to assess patterns of connectivity when a person is not performing a task. These are different observations, not interchangeable versions of the same measurement.
The controls are scheduled for a sleep study at entry to exclude sleep disorders, while their motor, neuropsychological and MRI assessments are planned at baseline and annually for three years. Comparing repeated observations across the two groups may help the researchers identify which features change during follow-up and which differences are already present at the start.
Following people once could show a snapshot. Returning to the same participants each year creates a record of change, which is necessary for a question about progression. The proposed prognostic model would combine those clinical, cognitive, sleep and MRI measurements to estimate individual evolution. The registry describes the intended design; it does not show that the combination will outperform any single measurement.
A measurement plan is not yet a validated forecast
The study’s stated objective is to identify people with longstanding iRBD who may be at greater risk of converting to clinically defined Parkinson’s disease over a shorter time horizon. Reaching that objective would require more than finding differences between patients and controls or observing that some measurements change.
Researchers would need to show how accurately the model anticipates later diagnoses, whether its estimates are well calibrated, and whether it works in an appropriate group beyond the center where it was developed. They would also need evidence that using those estimates leads to better decisions or outcomes. The supplied record does not establish predictive accuracy, independent validation or clinical usefulness.
The planned enrollment of 100 people also does not establish how many participants have enrolled, completed follow-up or developed Parkinson’s disease. The current registry record lists the study as active but not recruiting, with an actual start date of December 4, 2020, an estimated primary completion date of June 1, 2027, and an estimated completion date of August 1, 2027. Those dates describe the registry’s study lifecycle and plans, not completed findings.
For the same reason, an association between an MRI feature and later progression would not show that the feature causes progression. Nor would a future risk estimate prove that Parkinson’s disease could be prevented or that acting on the estimate would improve care. The narrow, high-risk cohort limits any conclusion about screening people in the general population.
What better risk estimates could mean for patients and trials
If this follow-up produces a dependable way to distinguish which people with longstanding iRBD are more likely to progress during a defined period, future researchers could assemble clinical-trial groups with more informative expectations about disease evolution. That could make studies of early Parkinson’s disease easier to design and interpret, provided the model works in relevant patients and remains accurate outside its original setting.
For patients, reliable individual estimates could eventually support more tailored clinical follow-up rather than treating everyone with the same timeline. That possibility depends on evidence that the estimates are accurate, understandable and useful in real decisions. The registry describes an investigation that may help test that idea; it does not promise a treatment, prevention strategy or validated risk test.
Key Sources
- Primary source: Predicting Parkinson's Disease Before It Strikes: A Brain Imaging Study in At-Risk Individual
Government or Regulator · Clinical Trial · 2026-07-28